House dust mite allergy vaccine - Circassia

Drug Profile

House dust mite allergy vaccine - Circassia

Alternative Names: ToleroMune HDM; ToleroMune house dust mite

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator Circassia
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptide vaccines; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis

Most Recent Events

  • 28 Jul 2015 Phase-II development is ongoing in Canada, France, Germany, Italy, Netherlands, South Africa, Spain and USA
  • 01 Sep 2014 Phase-II clinical trials in Allergic rhinoconjunctivitis in USA, Germany, Italy and the Netherlands (Intradermal) (NCT02150343)
  • 27 May 2014 Circassia plans a phase II trial for rhinoconjunctivitis in USA, Canada & European Union (NCT02150343)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top